Original ResearchClinical—Alimentary TractOnce-Daily Budesonide MMX® Extended-Release Tablets Induce Remission in Patients With Mild to Moderate Ulcerative Colitis: Results From the CORE I Study
Section snippets
Materials and Methods
All authors had access to the study data and reviewed and approved the final manuscript.
Patients
Supplementary Figure 1 shows the disposition of patients. A total of 489 patients were included in the modified ITT population. Twenty randomized patients were excluded from the modified ITT analysis because of normal histology at baseline (17 patients) or major entry criteria violations (3 patients with confirmed infectious colitis at study entry). The baseline characteristics were similar across the treatment groups, except that the percentage of male patients in the budesonide MMX 9 mg group
Discussion
Treatment with budesonide MMX 9 mg showed a significant benefit over placebo in the rate of combined clinical and endoscopic remission at week 8 among patients with active, mild to moderate UC. Exploratory analyses suggested a possible benefit for symptom resolution, and there were trends toward greater rates of clinical improvement and endoscopic improvement. Incidence rates of treatment-emergent adverse events were similar across treatment groups, and no clinically important safety trends
References (35)
- et al.
European evidence-based consensus on the management of ulcerative colitis: current management
J Crohns Colitis
(2008) - et al.
American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease
Gastroenterology
(2006) - et al.
Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: a dose-ranging studyU.S. Budesonide enema study group
Gastroenterology
(1998) - et al.
Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States
Am J Gastroenterol
(2002) - et al.
Budesonide versus prednisone in the treatment of active Crohn's diseaseThe Israeli Budesonide Study Group
Gastroenterology
(1998) - et al.
Oral budesonide as maintenance treatment for Crohn's disease: a placebo- controlled, dose-ranging studyCanadian Inflammatory Bowel Disease Study Group
Gastroenterology
(1996) - et al.
Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis
Gastroenterology
(1996) - et al.
Clinical trial: preliminary efficacy and safety study of a new Budesonide-MMX(R) 9 mg extended-release tablets in patients with active left-sided ulcerative colitis
J Crohns Colitis
(2010) - et al.
5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis
Gastroenterology
(1987) - et al.
A review of activity indices and efficacy endponts for clinical trials of medical therapy in adults with ulcerative colitis
Gastroenterology
(2007)
Once-daily high concentration MMX mesalamine in active ulcerative colitis
Gastroenterology
Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis
Clin Gastroenterol Hepatol
Indium 111-granulocyte scanning in the assessment of disease extent and disease activity in inflammatory bowel diseaseA comparison with colonoscopy, histology, and fecal indium 111-granulocyte excretion
Gastroenterology
Budesonide-MMx® 9 mg for induction of remission of mild-to-moderate ulcerative colitis (UC): data from a multicenter, randomized, double-blind placebo-controlled study in Europe, Russia, Israel and Australia
Gastroenterology
Ulcerative colitis
Lancet
Cortisone in ulcerative colitisFinal report on a therapeutic trial
BMJ
Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee
Am J Gastroenterol
Cited by (0)
Conflicts of interest The authors disclose the following: Dr Sandborn has received consulting fees from Abbott Laboratories, ActoGeniX NV, AGI Therapeutics Inc, Alba Therapeutics Corp, Albireo, Alfa Wasserman, Amgen, AM-Pharma BV, Anaphore, Astellas, Athersys Inc, Atlantic Healthcare Ltd, Aptalis, BioBalance Corp, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene Corp, Celek Pharmaceuticals, Cellerix SL, Cerimon Pharmaceuticals, ChemoCentryx, CoMentis, Cosmo Technologies, Coronado Biosciences, Cytokine PharmaSciences Inc, Eagle Pharmaceuticals, enGene Inc, Eli Lilly and Company, EnteroMedics, Exagen Diagnostics Inc, Ferring Pharmaceuticals, Flexion Therapeutics Inc, Funxional Therapeutics Ltd, Genzyme Corp, Gilead Sciences, Given Imaging, GlaxoSmithKline, Human Genome Sciences, Ironwood Pharmaceuticals, KaloBios Pharmaceuticals Inc, Lexicon Pharmaceuticals, Lycera Corp, Meda Pharmaceuticals, Merck Research Laboratories, Merck Serono, Millennium Pharmaceuticals, Nisshin Kyorin Pharmaceuticals, Novo Nordisk, NPS Pharmaceuticals, Optimer Pharmaceuticals, Orexigen Therapeutics Inc, PDL BioPharma, Pfizer Inc, Procter & Gamble, Prometheus Laboratories, ProtAb Ltd, PurGenesis Technologies Inc, Relypsa Inc, Roche, Salient Pharmaceuticals, Salix Pharmaceuticals, Santarus Inc, Schering-Plough, Shire Pharmaceuticals, Sigmoid Pharma Ltd, Sirtris Pharmaceuticals, SLA Pharma UK Ltd, Targacept, Teva Pharmaceuticals, Therakos, Tillotts Pharma AG, TxCell SA, UCB Pharma, Viamet Pharmaceuticals, Vascular Biogenics Ltd, Warner Chilcott UK Ltd, and Wyeth; has received research grants from Abbott Laboratories, Bristol-Myers Squibb, Genentech, GlaxoSmithKline, Janssen, Millennium Pharmaceuticals, Novartis, Pfizer, Procter & Gamble, Shire Pharmaceuticals, and UCB Pharma; has received payments for lectures/speakers bureau from Abbott Laboratories, Bristol-Myers Squibb, and Janssen; and holds stock/stock options in EnteroMedics. Dr Travis has received consulting fees from Abbott Laboratories, Asahi, Aspreva, Cosmo Technologies, Elan, Ferring Pharmaceuticals, Genzyme Corp, Genentech, Glenmark, GlaxoSmithKline, Lexicon Pharmaceuticals, Merck Research Laboratories, Merck Serono, Millennium Pharmaceuticals, Nisshin Kyorin Pharmaceuticals, Novo Nordisk, NPS Pharmaceuticals, PDL BioPharma, Pfizer Inc, Procter & Gamble, Santarus Inc, Schering-Plough, Shire Pharmaceuticals, Sigmoid Pharma Ltd, Tillotts Pharma AG, TxCell SA, UCB Pharma, Vertex, Vifor, Warner Chilcott UK Ltd, and Wyeth; has received research grants from Abbott, Bristol-Myers Squibb, Genentech, GlaxoSmithKline, Janssen, Novartis, Pfizer Inc, Procter & Gamble, Shire Pharmaceuticals, and UCB Pharma; has received payments for lectures/speakers bureau from Abbott Laboratories, Ferring Pharmaceuticals, Merck, Shire Pharmaceuticals, Tillotts, Warner Chilcott, and Vertex; and holds no stock/stock options. Dr Moro and Dr Jones are employees of and own stock in Cosmo Pharmaceuticals SpA. Drs Ballard, Bagin, Huang, and Yeung and Ms Gautille are employees of and own stock in Santarus, Inc.
Funding Supported by Santarus, Inc, and Cosmo Pharmaceuticals SpA.